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Malignant Hyperthermia
Jessica K. Joos RN, BSN, CCRN-CMC
Otterbein University, Westerville, Ohio
Pathophysiological Processes
Pathophysiology
•

MH can be induced by volatile anesthetic gases and
neuromuscular blocking agents such as succinylcholine
(Yang et al., 2020).
Stimulated ryanodine receptors cause the sarcoplasmic
reticulum to release excess calcium leading to
“uncontrolled skeletal muscle hypermetabolism” (Yang et
al., 2020).
This hypermetabolism creates heat (Yang et al., 2020).
The heat leads to elevated temperature, acidosis,
hypoxemia, hypercarbia, rhabdomyolysis (Yang et al.,
2020).
If left untreated, MH will progress into renal and
circulatory overload becoming fatal (Yang et al., 2020).

•

Figure 1 Retrieved from
https://www.ha.org.hk/haho/ho/pspa_mirp/MSB15.pdf

Introduction
•
•

•
•
•

Malignant Hyperthermia (MH) is a disorder affecting skeletal
muscle metabolism (Riazi et al., 2018).

MH must be detected and treated early to promote minimal
complications and effective recovery.

•

Presuming that the patient will not have an MH event because
of uneventful anesthetic exposure previously may delay
diagnosis (Hopkins et al., 2020).

•

One cannot provide anesthesia without being knowledgeable
of MH.

•

•
•

•
•

The prevelance of MH is about 1 in 100,000 with a higher
prevalence in the male population (Yang, Tautz, Zhang,
Fomina, & Liu, 2020).

•

Nursing Implications
•

•

•

Figure 3 Retrieved from Yang, Tautz, Zhang, Fomina, and Liu (2020).

Signs and Symptoms
•

Figure 2 Retrieved from
href='https://www.freepi
k.com/vectors/heat'>Heat
vector created by brgfx www.freepik.com</a>

Signs include elevated temperature, hypercarbia,
hypoxemia, acidosis, and muscle rigidity (Yang et al., 2020).

•

Clinical signs may be nonspecific and may subside if
triggering factor is removed (Riazi, Kraeva &Hopkins, 2018).

•

Early signs include rise in end-tidal CO2 and heart rate and
may or may not have a rise in temperature (Riazi, Kraeva &
Hopkins, 2018).

Delays in treatment increase
mortality rate and the severity of
complications (Hopkins et al.,
2020).
Step One: Identify and
discontinue triggering agent and
provide 100% oxygen at
maximum flow.
Step Two: Administer Dantrolene.
Dantrolene is a ryanodine
receptor antagonist causing
decreased release of calcium to
stop MH physiology (National
Library of Medicine, 2022).
Step Three: Initiate active body
cooling as needed.
Step Four: Manage acidosis with
hyperventilation and
administration of sodium
bicarbonate as needed.
Step Five: Treat hyperkalemia
with administration of sodium
bicarbonate, insulin, and glucose.
Avoid giving calcium.
Step Six: Monitor and treat any
complications that arise including:
arrhythmias, disseminated
intravascular coagulopathy (DIC),
myoglobinuria, and compartment
syndrome.
(Steps one through six adapted
from Hopkins et al., 2020)

Conclusion
•

MH is a current issue in
anesthesia requiring attention.

•

Early identification is essential.

•

MH is easily reversible and side
effects can be managed when
promptly diagnosed by the
anesthesia provider.

Percentage of Appearance of Clinical
Symptoms During 255 MH Events
Figure 3 Retrieved from MHAUS (2022)

CLINICAL SYMPTOM

PERCENT OF
APPEARANCE
(%)

Masseter Spasm

26.7

Hypercarbia

92.2

Sinus Tachycardia

72.9

Generalized Muscle
Rigidity

40.8

Tachypnea

27.1

MH Resources

Cyanosis

9.4

Skin Mottling

6.3

Malignant Hyperthermia
Association of the
United States
https://www.mhaus.org/

Rapidly Increasing
Temperature

64.7

Elevated Temperature

52.2

Sweating

17.6

Ventricular Tachycardia

3.5

Cola-colored urine

13.7

Ventricular Fibrillation

2.4

Excessive Bleeding

2.7

24-HOUR MH HOTLINE
800-644-9737
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